

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

			· · · · · · · · · · · · · · · · · · ·			
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/882,945	06/15/2001	Victor Lyamichev	FORS-04586	9139		
23535 7	7590 08/27/2002					
MEDLEN & CARROLL, LLP 101 HOWARD STREET SUITE 350			EXAMINER			
			CHAKRABARTI, ARUN K			
SAN FRANCI	SCO, CA 94105		ART UNIT	PAPER NUMBER		
			L	- 10		
			1634	10 -		
			DATE MAILED: 08/27/2002			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.	Applicant(s)				
		09/882,945		LYAMICHEV ET AL.				
	Office Action Summary	Examiner		Art Unit				
		Arun Chakr	abarti	1634				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status 1)	Responsive to communication(s) filed on							
2a)□	•	—· is action is n	on-final					
3)□	,			osecution as to the merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>								
4)⊠	Claim(s) 1-51 is/are pending in the application	1.						
	4a) Of the above claim(s) is/are withdrav	wn from cons	sideration.					
5)	5) Claim(s) is/are allowed.							
6)	6) Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)⊠	Claim(s) <u>1-51</u> are subject to restriction and/or e	election requ	irement.					
Application Papers								
9)☐ The specification is objected to by the Examiner.								
10)	The drawing(s) filed on is/are: a)□ accep	pted or b)☐ c	bjected to by the Exar	miner.				
	Applicant may not request that any objection to the	-						
11)	The proposed drawing correction filed on			ved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No								
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>								
Attachment(s)								
1)  Notice 2)  Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) _			(PTO-413) Paper No(s) Patent Application (PTO-152) tion .				

Application/Control Number: 09/882,945

Art Unit: 1634

## **DETAILED ACTION**

## Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-43, drawn to nucleic acid amplification, classified in class 435, subclass91.2.
  - II. Claims 44-47 and 50-51, drawn to nucleic acid hybridization, classified in class435, subclass 6.
  - III. Claims 48-49, drawn to nucleic acids, classified in class 536, subclass 22.1.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions of Groups I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of nucleic acid amplification of Group I is not disclosed as capable of use together with nucleic acid hybridization of Group II and they have different modes of operation, different functions, or different effects.
- 3. Inventions of Groups I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP §

Application/Control Number: 09/882,945 Page 3

Art Unit: 1634

806.05(h)). In the instant case, the nucleic acids of Group III can be used in the amplification of Group I or can be used to make RNA and protein or can be used to make antisense nucleic acids for gene therapy.

- 4. Inventions of Groups II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the nucleic acids of Group III can be used in the hybridization of Group II or can be used to make RNA and protein or can be used to make antisense nucleic acids for gene therapy.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 6. Claim 44-51 are generic to a plurality of disclosed patentably distinct species comprising 154 distinct nucleic acid sequences. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Application/Control Number: 09/882,945 Page 4

Art Unit: 1634

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

7. A telephone call was made to David Casimir on August 14, 2002 to request an oral election to the above restriction requirement, but did not result in an election being made

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CAR 1.143).

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CAR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CAR 1.48(b) and by the fee required under 37 CAR 1.17(I).

## Conclusion

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D. whose telephone number is (703) 306-5818.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152. Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission via the P.T.O. Fax Center located In

Art Unit: 1634

Crystal Mall 1. The CM1 Fax Center numbers for Technology Center 1600 are either (703) 305-3014 or (703) 308-4242. Please note that the faxing of such papers must conform with the Notice to Comply published In the Official Gazette, 1096 OG 30 (November 15, 1989).

Arun Chakrabarti

Patent Examiner

Art Unit 1634,

August 14, 2002

W. Gary Jones

Supervisory Patent Examiner Technology Center 1600